CHITA – a registry of in vitro NAMs
If we want to replace animal testing in biomedical research, how do we find human-relevant alternatives? It’s not that simple. There are 1000s of human cell-based assays and systems that…
Faster adoption of alternatives to animals in biomedical research is a worthy goal for both scientific and ethical reasons. Addressing key elements of technology readiness for cell-based alternatives (in vitro…
A strong chain of translatability is crucial for successful drug discovery programs. The chain of translatability is a molecular-level association between the mechanisms that drive the assay phenotype, the preclinical disease…
VCAM-1 is one of our favorite biomarkers. The levels of this clinical biomarker are increased in patients with diseases as diverse as Parkinson’s disease and arthritis. The regulation of VCAM-1…
It’s not just about measuring what matters – it’s about making what you measure matter. There are many options for endpoints to measure in phenotypic assays. Endpoints to consider include…
Developing phenotypic assays that model human disease is a heavy lift. Our understanding of disease biology is limited. And there are so many variables, it’s hard to know where to…
How do we design phenotypic assays that are physiologically relevant? And what do we mean by “relevant”? For those of us working in drug discovery or chemical safety, what we…
The selection of chemical matter to be used for screening is a major discussion topic for phenotypic drug discovery (PDD) researchers. At the recent Keystone Symposium on PDD, several talks were…
